Loading…
← CockpitCompetitor Analysis › ACL.AX Australian Clinical Labs LtdOpen in the cockpit ↗

Australian Clinical Labs LtdACL.AXCompetitor analysis, valuation and peers

Australia · AUD·Health Care›Medical/Nursing Services
Momentum leader 96
Mkt cap
$418M
US dollars, full cap
Free float
84%
of shares outstanding
$/day
$1.48M
20-day average traded
Fwd P/E
17.8×
forward earnings
ROIC−WACC
-0.1 pp
WACC 9.0%
Hurdle
+2 pp
Req g minus delivered
Next earnings
97 days
23 Feb 2027
Close · AUDA$3.33
1D-0.6%
1W+0.3%
1M+14.8%
3M+12.5%
6M+67.8%
YTD+21.1%
1Y+20.2%
ATR %2.5%
52w lowhigh1.8% off high

What Australian Clinical Labs does

Employees: 4,500

Australian Clinical Labs at a glance

Size Australian Clinical Labs (ACL.AX) is an Australia Health Care company (Medical/Nursing Services) with a market value of $418M, the 275th largest of 317 Australia companies the cockpit tracks. Shares closed at A$3.33 on 18 Nov 2026.

Performance Over six months the shares gained 67.8%, against -4.0% for the median peer and +1.2% for the Australia market (cap-weighted) — highest of 20 in its peer set.

Growth Revenue fell 0.9% over the last twelve months (peer median +6.0%); the operating margin is 8.0% (peer median 8.3%).

Valuation It trades at 17.8× forward earnings against a peer median of 16.9× (6th most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.1 points below its cost of capital (9.0% WACC).

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026ACL.AX 165Peer median 96
Six months, rebased to 100: Australian Clinical Labs against the median of its 20 peers (local-currency closes).

Australian Clinical Labs financials

Reported figures in AUD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueA$730MA$730MA$736MA$690MA$692M
Revenue growth—-1%+7%0%—
Gross profitA$150MA$150MA$153MA$138MA$146M
EBITDAA$194MA$197MA$199MA$185MA$179M
Net incomeA$23.7MA$23.7MA$32.4MA$23.9MA$35.9M
Free cash flowA$154MA$154MA$174MA$153MA$137M
Capital expenditureA$9.58MA$9.58MA$8.41MA$6.50MA$6.93M
Total debtn/aA$337MA$290MA$309MA$316M

Quarterly statements and history in the cockpit →

Australian Clinical Labs competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%IDXJSLLSRTA9860127120M12AYUPA301060300642NIOXDNAAUNADRAGARWQWELLFLGTNEPHROPLUSGMRSACL.AX6-month return →1-month return →
Up and to the right = strong over both horizons. Australian Clinical Labs is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×25×50×75×IDXJSLLSRTA9860M12NIOXAUNA3218WELLNEPHROPLUSGMRS1951ACL.AXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Australian Clinical Labs is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%IDXJSLL9860M12AYUPA301060300642AUNA3218DRAGARWQWELLNEPHROPLUSGMRS1951ACL.AXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Australian Clinical Labs is the large dot.

Australian Clinical Labs competitors and peer comparison

How Australian Clinical Labs compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Australian Clinical Labs against its 20 peers (data as of 18 Nov 2026)
MeasureACL.AXPeer medianRank in peer set
1-month return+14.8%-9.6%3rd highest of 21
6-month return+67.8%-4.0%highest of 20
Distance from 52-week high-1.8%-30.8%highest of 21
Revenue growth (TTM)-0.9%+6.0%5th lowest of 21
Operating margin8.0%8.3%11th highest of 21
Forward P/E17.8×16.9×6th most expensive of 13
Growth the price implies (Req g, 7 yrs)4.3%6.6%7th least demanding of 17
Growth delivered (Del g)+2.6%+16.6%4th lowest of 17
Hurdle (Req g minus delivered)+1.7 pp-13.8 pp6th most demanding of 17
ROIC minus cost of capital-0.1 pp-2.5 pp9th highest of 20
EV / EBITDA4.8×9.8×2nd cheapest of 13
Net debt / EBITDA1.6×1.5×7th most indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Australian Clinical Labs ACL.AXAustralia$418M+68%-1%8%17.8×4.3%+2.6%
Integral Diagnostics IDX.AXAustralia$413M-22%+26%9%14.7×7.8%+17.7%
Jeena Sikho Lifecare JSLL.NSIndia$394M-55%+135%32%17.4×7.3%+42.6%
Strata Critical Medical SRTAUnited States$443M-10%+23%-4%86.3×n/an/a
ADICON 9860.HKHong Kong$393M+5%+1%4%24.6×12.3%-1.5%
JS Link 127120.KSSouth Korea$458M-62%+39%-83%n/an/an/a
M1 Kliniken M12.DEGermany$368M+1%-28%13%16.4×-5.3%+17.9%
Australian Unity Ltd Pref AYUPA.AXAustralia$352M+17%0%-2%n/a-14.9%+9.6%
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%n/a5.9%+3.2%
Tellgen 300642.SZChina$328M-11%+5%8%n/a18.8%-5.8%
Oncology Institute STLNUnited States$326Mn/a+35%-3%n/a5.4%+21.8%
NIOX NIOX.LUnited Kingdom$325M+3%+3%22%19.8×3.4%+15.3%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%n/an/an/a
Auna AUNAUnited States$309M-5%+17%13%4.1×-10.7%+24.4%
Universal Vision Biotechnology 3218.TWOTaiwan$309M-4%+5%31%9.2×-13.8%+15.4%
Dr. Agarwal'S Eye Hospital DRAGARWQ.NSIndia$292M+14%+20%21%n/a19.6%+27.5%
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%

Questions

Which companies are Australian Clinical Labs's closest peers?
The cockpit's peer set: Integral Diagnostics (IDX.AX), Jeena Sikho Lifecare (JSLL.NS), Strata Critical Medical (SRTA), ADICON (9860.HK), JS Link (127120.KS), M1 Kliniken (M12.DE), Australian Unity Ltd Pref (AYUPA.AX), Shanghai Labway Clinical Laboratory (301060.SZ).
Is Australian Clinical Labs expensive compared with its peers?
On forward p/e it trades at 17.8× against a peer median of 16.9×, 6th most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Australian Clinical Labs stock performed?
Over six months to 18 Nov 2026 the shares returned +67.8% against -4.0% for the median peer; over one year +20.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.